Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury

Macher, Hada C.; Egea-Guerrero, Juan José; Revuelto-Rey, J.; Gordillo-Escobar, E.; Enamorado-Enamorado, J.; Boza, Antonio; Rodriguez, Ana; Molinero, Patrocinio; Guerrero, Juan M.; Domínguez-Roldán, José María; Murillo-Cabezas, Francisco; Rubio, Amalia

doi:10.1016/j.cca.2012.08.001

Cited by 84 publications

(79 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27 Levels of ctDNA in blood can vary widely between patients due to differences in tumor DNA release mechanisms and the effectiveness of cfDNA clearance, with estimates of the proportion of ctDNA from total cfDNA varying from 0.01% to 90%. 20,28 Serum cfDNA levels are significantly higher than plasma levels 20,[29][30][31][32][33] due to clotting of white blood cells in the collection tube, leading to their lysis. 20,32,33 Consequently, serum ctDNA is diluted by genomic DNA released from white blood cells, and plasma is preferred as a source of ctDNA.…”

Section: Liquid Biopsy Using Ctdna In Bloodmentioning

confidence: 99%

Future perspectives of circulating tumor DNA in colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Tumor biopsy is currently the gold standard for diagnosis and in determining cell signaling pathways involved in the development of treatment resistance. However, there are major challenges with this technique, including the need for serial sampling to monitor treatment resistance, which is invasive and also has the potential for selection bias due to intra-tumoral and inter-tumoral heterogeneity. These challenges highlight the need for more effective methods for obtaining Tumor samples. Liquid biopsy analyzes genetic material or tumor cells shed into the blood from the primary tumor and metastatic sites and consequently provides a comprehensive, real-time picture of the tumor burden in an individual patient. Indeed, liquid biopsy has the potential to revolutionize cancer management. Here, we review recent studies on the potential clinical applications of liquid biopsy using circulating tumor DNA in colorectal cancer, including screening, diagnosis, detection of minimal residual disease after surgery, detection of recurrence, prognosis, predicting treatment response, monitoring tumor burden or response during treatment, and tracking resistance. We also discuss recent data demonstrating the utility of detecting KRAS-mutated circulating tumor DNA, both at diagnosis to determine an appropriate treatment strategy and during anti-epidermal growth factor receptor therapy to predict treatment resistance. The future integration of liquid biopsy into clinical practice is discussed, together with alternative approaches and key questions that need to be answered in future clinical studies before this technology can be implemented and used routinely.

show abstract

Section: Liquid Biopsy Using Ctdna In Bloodmentioning

confidence: 99%

Future perspectives of circulating tumor DNA in colorectal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Since its discovery, cfDNA has been found to be increased in a variety of neoplastic and non-neoplastic diseases of humans, including myocardial infarction (Chang et al 2002), rheumatoid arthritis (Zhong et al 2007), severe viral infections (Ha et al 2011), stroke , sepsis (Martins et al 2000;Rhodes et al 2006) and severe trauma (Lo et al 2000;Lam et al 2003;Macher et al 2012). In all these diseases, the cfDNA concentrations have correlated with disease severity and prognosis.…”

Section: Introductionmentioning

confidence: 99%

Investigation of cell-free DNA in canine plasma and its relation to disease

Burnett

Cave

Gedye

et al. 2016

Veterinary Quarterly

View full text Add to dashboard Cite

Background: DNA is released from dying cells during apoptosis and necrosis. This cell-free DNA (cfDNA) diffuses into the plasma where it can be measured. In humans, an increase in cfDNA correlates with disease severity and prognosis. Objective: It was hypothesized that when DNA in canine plasma was measured by emission fluorometry without prior DNA extraction, the concentration of cfDNA would increase with disease severity. Animals: The diseased population consisted of 97 client-owned dogs. The clinically normal population consisted of nine client-owned dogs presenting for 'wellness screens', and 15 colony-owned Harrier Hounds. Methods: Plasma cfDNA was measured by fluorometry without prior DNA extraction. The effects of ex vivo storage conditions were evaluated in plasma from two clinically normal dogs. In all other dogs, plasma was separated within two hours of collection. The association between the cfDNA concentration in hospitalized dogs and a variety of clinical, clinicopathological and outcome variables was tested. Results: The concentration of cfDNA was reliably measured when plasma was separated within two hours of blood collection. The diseased dogs had significantly higher cfDNA than clinically normal dogs (P < 0.001), and the more severe the disease, the higher the cfDNA when severity was categorized according to the American Society of Anesthesiologists (ASA) status (P < 0.001). Dogs that did not survive to discharge had significantly higher cfDNA concentrations than survivors (P D 0.02). Conclusions/Clinical Importance: The concentration of cfDNA in the plasma of diseased dogs is associated with disease severity and prognosis. Measurement of canine cfDNA could be a useful non-specific disease indicator and prognostic tool.

show abstract

“…After an initial peak, a higher decrease was detected within the first 24 h among survivors compared with non-survivors. 27 Therefore, our aim was to investigate in a large sample of patients with severe TBI whether plasma DNA concentrations correlated to short-term primary outcome (survival or death) and Glasgow Coma Scale (GCS) scores within the first 24 h after injury.…”

Section: Introductionmentioning

confidence: 99%

“…47,48 Previous studies investigating plasma cell-free DNA and trauma showed association of increased plasma cell-free DNA levels with both injury severity and the development of post-traumatic complications. 27,40,41 In a previous study, our group has demonstrated that high concentrations of plasmatic cell-free DNA correlated to…”

mentioning

confidence: 99%

Elevated Cell-Free Plasma DNA Level as an Independent Predictor of Mortality in Patients with Severe Traumatic Brain Injury

Filho

Simon

Ikuta

et al. 2014

Journal of Neurotrauma

View full text Add to dashboard Cite

Trauma is the leading cause of death in individuals less than 45 years old worldwide, and up to 50% of trauma fatalities are because of brain injury. Prediction of outcome is one of the major problems associated with severe traumatic brain injury (TBI), and research efforts have focused on the investigation of biomarkers with prognostic value after TBI. Therefore, our aim was to investigate whether cell-free DNA concentrations correlated to short-term primary outcome (survival or death) and Glasgow Coma Scale (GCS) scores after severe TBI. A total of 188 patients with severe TBI were enrolled in this prospective study; outcome variables comprised survival and neurological assessment using the GCS at intensive care unit (ICU) discharge. Control blood samples were obtained from 25 healthy volunteers. Peripheral venous blood was collected at admission to the ICU. Plasma DNA was measured using a real-time quantitative polymerase chain reaction (PCR) assay for the b-globin gene. There was correlation between higher DNA levels and both fatal outcome and lower hospital admission GCS scores. Plasma DNA concentrations at the chosen cutoff point ( ‡ 171,381 kilogenomesequivalents/L) predicted mortality with a specificity of 90% and a sensitivity of 43%. Logistic regression analysis showed that elevated plasma DNA levels were independently associated with death ( p < 0.001). In conclusion, high cell-free DNA concentration was a predictor of short-term mortality after severe TBI.

show abstract

Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury

Cited by 84 publications

References 33 publications

Future perspectives of circulating tumor DNA in colorectal cancer

Future perspectives of circulating tumor DNA in colorectal cancer

Investigation of cell-free DNA in canine plasma and its relation to disease

Elevated Cell-Free Plasma DNA Level as an Independent Predictor of Mortality in Patients with Severe Traumatic Brain Injury

Contact Info

Product

Resources

About